scholarly journals Inverse Prognostic Relationships of 18F-FDG PET/CT Metabolic Parameters in Patients with Distal Bile Duct Cancer Undergoing Curative Surgery

2018 ◽  
Vol 52 (5) ◽  
pp. 334-341 ◽  
Author(s):  
Hyun Kyung Yi ◽  
Yong-Jin Park ◽  
Ji Hoon Bae ◽  
Jong Kyun Lee ◽  
Kwang Hyuk Lee ◽  
...  
2020 ◽  
Vol 7 (6) ◽  
pp. 520-525
Author(s):  
Fadime Demir ◽  
Ahmet Yanarateş

Objective: This study aimed to investigate the relationship between 18Fluorine-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) parameters and hematological parameters in squamous cell lung cancer without distant metastasis and to investigate the prognostic value of these parameters. Patients and Methods: This study included 155 patients who underwent 18F-FDG PET/CT imaging for squamous cell lung cancer. Metabolic and hematological parameters were analyzed. Metabolic parameters included maximum and mean standardized uptake values (SUVmax and SUVmean), metabolic tumor volume (MTV), total lesional glycolysis (TLG), and maximum tumor-to-blood SUV ratio (SURmax). Hematological parameters included neutrophil, lymphocyte, platelet, neutrophil/lymphocyte count ratio (NLR), and platelet/lymphocyte count ratio (PLR) Results: Overall survival was significantly shorter in patients with TLG > 194, NLR > 3.3, and PLR > 157.2 (p < 0.001, p = 0.001, and p = 0.001, respectively). There was a poor correlation between TLG and NLR (p < 0.001, r = 0.302), TLG and PLR (p < 0.001, r = 0.304). TLG (> 194; hazard ratio 1.704, 95% CI 1.056–2.751, p = 0.027) and Tumor-Node-Metastasis (TNM)-based staging (stage II; hazard ratio 1.965, 95% CI 0.739–5.227, p = 0.019) were independent prognostic factors for overall survival. Conclusion: While PET/CT metabolic parameters had both predictive and independent prognostic values in squamous cell lung cancers, PLR and NLR had only predictive values. It shows that PET/CT metabolic parameters related to the course of the disease are more valuable than hematological parameters in squamous cell lung cancer.


2010 ◽  
Vol 37 (3) ◽  
pp. 327-333 ◽  
Author(s):  
Shao-li Song ◽  
Chuang Deng ◽  
Ling-feng Wen ◽  
Jian-jun Liu ◽  
Hui Wang ◽  
...  

Author(s):  
Virginia Liberini ◽  
Marco Rubatto ◽  
Riccardo Mimmo ◽  
Roberto Passera ◽  
Francesco Ceci ◽  
...  

Background/Aim: To evaluate the association between baseline [18F]FDG-PET/CT tumor burden parameters and disease progression rate after first-line target therapy or immunotherapy in advanced melanoma patients. Materials and Methods: 44 melanoma patients who underwent [18F]FDG-PET/CT before first-line target therapy (28/50) or immunotherapy (16/50) were retrospectively analyzed. Whole-body and per-district metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated. Therapy response was assessed according to RECIST 1.1 on CT scan at 3 (early) and 12 (late) months. PET parameters were compared with Mann-Whitney test. Optimal cut-offs for predicting progression were defined using the ROC curve. PFS and OS were studied using Kaplan-Meier analysis. Results: Median(IQR) MTVwb and TLGwb were 13.1 mL and 72.4 respectively. Non-responders patients were 38/44, 26/28 and 12/16 at early evaluation, and in 33/44, 21/28 and 12/16 at late evaluation in the whole-cohort, target and immunotherapy subgroup respectively. At late evaluation, MTVbone and TLGbone were higher in non-responders compared to responder patients (all p&lt;0.037) in the whole-cohort and target subgroup and also MTVwb and TLGwb (all p&lt;0.022) in target subgroup. No significant differences were found for immunotherapy subgroup. No metabolic parameters were able to predict PFS. Controversy, MTVlfn, TLGlfn, MTVsoft+lfn, TLG-soft+lfn, MTVwb and TLGwb were significantly associated (all p&lt;0.05) with OS in both the whole-cohort and target therapy subgroup. Conclusion: Higher values of whole-body and bone metabolic parameters were correlated with poorer outcome, while higher values of whole-body, lymph node and soft tissue metabolic parameters were correlated with OS.


Metabolites ◽  
2021 ◽  
Vol 12 (1) ◽  
pp. 7
Author(s):  
Daniel Hueng-Yuan Shen ◽  
Hung-Pin Chan ◽  
Fu-Ren Tsai ◽  
Chin Hu ◽  
Allan Yi-Nan Chen ◽  
...  

Esophageal squamous cell carcinoma (ESCC) is a major cancer prevalent in Asian males. Pretreatment tumor burden can be prognostic for ESCC. We studied the prognostic value of metabolic parameters of 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) and the serum squamous cell carcinoma antigen (SCC-Ag) level in node-negative stage II ESCC patients. Eighteen males underwent staging evaluation were included. The volume-based metabolic parameters derived from 18F-FDG PET/CT, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), were obtained using the PET Volume Computer Assisted Reading application. The Spearman correlation coefficients were calculated to assess the relationship between metabolic parameters and pretreatment serum SCC-Ag levels. Based on the 5-year follow-up, patients were sub-divided into the demised and the stable groups. Potential prognostic value was assessed by independent t-test and the Mann–Whitney U test. The association of overall survival was assessed using univariate and multivariate Cox regression analyses. The demised group showed significant higher values in serum SCC-Ag, as well as in MTV and TLG, but not SUVmax and SUVmean. The SUVmax, MTV, TLG, and serum SCC-Ag showed significant association with overall survival. Our findings suggest potential usage of pretreatment volume-based metabolic parameters of 18F-FDG PET/CT and serum SCC-Ag as prognostic factors for node-negative stage II ESCC patients.


Sign in / Sign up

Export Citation Format

Share Document